ANN ARBOR, Mich., Aug. 28, 2018 /PRNewswire/ -- Swift Biosciences today announced early access availability of its SwiftAmplicon HS Panels, a new, high-sensitivity targeted amplicon library preparation kit for next-generation sequencing (NGS) of liquid biopsy samples, including cell-free DNA (cfDNA). This addition to Swift's targeted NGS portfolio facilitates the detection
The first kit featuring the Swift Amplicon HS workflow is Swift's popular EGFR Pathway Panel, a focused cfDNA panel covering clinically relevant oncology hotspots including EGFR T790, KRAS G12/G13, NRAS Q61 and BRAF V600. Swift is also building custom panels and plans to release a Sample_ID panel for fetal/maternal tracing with the same sensitivity and specificity capabilities.
"Swift Amplicon HS represents an enabling tool for liquid biopsy and cell-free DNA applications, particularly with the many challenges associated with cfDNA templates and NGS-related errors that confound the detection of low frequency variants," said Drew McUsic, PhD, Swift's Amplicon product manager. "This kit is for translational labs who asked us for more confident variant calling at 1% frequency and below from cfDNA and also wanted the improved accuracy and reliability of the Illumina sequencing platform."
Nucleotide errors introduced during PCR and sequencing are removed through the implementation of unique molecular identifiers (MIDs or UMIs)—short barcodes that uniquely label target templates during amplification. Upon analysis, library molecules sharing the same unique identifiers are consolidated into consensus families, allowing for distinction between true positive variants versus those that were the result of assay artifacts. Swift offers cost-effective access to library generation with amplicons leveraging these MIDs.
Key features and benefits of the Swift Amplicon HS Panels include:
View original content:http://www.prnewswire.com/news-releases/swift-biosciences-launches-swift-amplicon-hs-panels-enabling-confident-targeted-detection-of-low-frequency-variants-from-liquid-biopsy-sequencing-300703058.html
SOURCE Swift Biosciences
Subscribe to our Free Newsletters!